The Efficacy of Suvorexant in the Residential Treatment of Patients with Substance Use Disorder and Insomnia: A Pilot Open Trial
Goal: Research has demonstrated that insomnia is a primary indicator of relapse and is a common problem in patients with substance use disorders. This medication, if effective, may be useful in patients with alcohol use disorders (AUDs) and opioid use disorders (OUDs).
Summary: In collaboration with Penn State/Hershey Medical Center, Caron is participating in an open trial of suvorexant, a drug used to treat insomnia, in patients with substance use disorders (opioid/alcohol) who have sleep disturbances. Suvorexant is an FDA approved medication for insomnia. Suvorexant differs from other sleep medications as it acts on the orexin 1 receptor. It has been reported to reduce cravings and normalize sleep in animal models. This medication may offer the potential to reduce craving as well as improve sleep, both of which would help to minimize the risk of relapse in individuals with substance use disorders.